Company News

On November 11, 2024, the Université de Sherbrooke (UdeS), the Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS) and bioMérieux, a world leader in the field of in vitro diagnostics, announce a three-year agreement to create a Canadian center of excellence dedicated to the fight against antimicrobial resistance and antibiotic stewardship.

On the sidelines of the 2024 United Nations High-Level Meeting on Antimicrobial Resistance (AMR), a multisectoral event titled “Advancing Together: Securing the Global AMR Agenda by Harnessing the Collective Strength of Multi-Sector Partnerships” took place on September 24 in New York. bioMérieux, in partnership with The Wellcome Trust, The American Society of Microbiology, Malawi, and the French Republic, organized the event to focus on fostering a collaborative ecosystem that establishes sustainable solutions across the entire AMR landscape. From diagnosis and treatment to surveillance and action plans, this initiative spanned human health, animals, and the environment.

bioMérieux, a world leader in in vitro diagnostics, celebrated the opening of the company’s Molecular Genomic Innovation Center in Philadephia, PA, on September 18th. The new 32,000 sq. ft. facility is home to the xPRO™ Program, which has rapidly changed the landscape of food safety diagnostic capabilities by partnering directly with industry leaders to address unmet needs to streamline operational efficiencies and further public health.

Two strategic infrastructures were inaugurated this year on the bioMérieux site of La Balme-les-Grottes (Isère, France): a plastic injection unit in June and a new-generation R&D building in September. The global specialist in in vitro diagnostics is continuing its investments in France, aiming to develop new solutions for public health worldwide.

SpinChip Diagnostics, in which bioMérieux has held an approximate 20% stake since March 2024, has just published results showing the very good performance of its high-sensitivity Point-of-Care (POC) cardiac troponin I (hs-cTnI) assay. This innovative assay, the first of its kind, could significantly improve the diagnosis of acute myocardial infarction.